Does Cabotegravir And Rilpivirine Interact with Mao Inhibitors?
CDI records a moderate classification for Cabotegravir And Rilpivirine and Mao Inhibitors. The stored summary is: CYP3A inhibitors may increase rilpivirine plasma concentrations. The mechanism involves inhibition of cyp3a-mediated metabolism of rilpivirine. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of CYP3A-mediated metabolism of rilpivirine
What To Tell Your Doctor or Pharmacist
If you are taking Cabotegravir And Rilpivirine and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider